Autosomal Recessive Progressive External Ophthalmoplegia (AR-PEO)

Autosomal recessive progressive external ophthalmoplegia is a rare, inherited mitochondrial muscle disease. “External ophthalmoplegia” means the eye-moving muscles slowly become weak, so the eyelids droop (ptosis) and the eyes move less and less over time. “Progressive” means it usually worsens over years. “Autosomal recessive” means a person inherits a faulty gene copy from each parent. AR-PEO is often caused by nuclear-gene defects that disturb mitochondrial DNA maintenance (for example, POLG, TWNK/C10orf2, RRM2B), so the muscle cells do not make energy efficiently. Symptoms mainly involve the eyes and eyelids, but some people also have limb or neck muscle weakness, exercise intolerance, neuropathy, hearing loss, or other features (sometimes called “CPEO-plus”). There is no cure yet, but supportive care can meaningfully improve comfort, safety, and daily function. NCBI+2NCBI+2

Autosomal recessive progressive external ophthalmoplegia (arPEO) is a rare, slowly worsening muscle disease that mainly affects the muscles that move the eyes and lift the eyelids. People usually first notice droopy eyelids (ptosis) and then reduced eye movements that get worse over years. The problem starts in the tiny “external” muscles around the eyes, so vision itself is usually normal at first, but looking up, down, or sideways becomes hard. Unlike sudden nerve palsies, arPEO changes are gradual. It is called autosomal recessive because a person gets one faulty gene from each parent. Many genes can cause it, most involved in mitochondria, the cell’s power plants. PMC+2NCBI+2

---

Other names

• Progressive external ophthalmoplegia (PEO) – the general clinical syndrome of ptosis and eye-movement weakness. “Autosomal recessive” specifies the inheritance type. PMC

• Chronic progressive external ophthalmoplegia (CPEO) – emphasizes the slow, long-term course. EyeWiki

• Mitochondrial PEO – highlights that most causes involve mitochondrial DNA maintenance problems. PubMed

• PEO may appear alone or with other features (sometimes called “CPEO+”). Related syndromes include Kearns–Sayre syndrome, but that has extra findings and is not the same condition. PubMed

---

Types

1. By gene (cause-based types). Several nuclear genes that look after mitochondrial DNA can cause arPEO when both copies are changed (recessive). Common ones include POLG, TWNK/PEO1, RRM2B, and SLC25A4 (ANT1). Others are rarer. All of them disturb mitochondrial DNA quality or amount in muscle, which weakens eye muscles first. NCBI+2MedlinePlus+2

2. By what you see in the muscle (biopsy-based types). Some people show multiple deletions of mitochondrial DNA in muscle cells; others have a single large deletion. Muscle often has ragged-red fibers and COX-negative fibers, classic mitochondrial myopathy changes. PubMed+1

3. By how wide-spread the problem is (phenotype).

• Pure arPEO: mostly eye muscles and lids.

• arPEO “plus”: eye findings plus other problems like limb weakness, neuropathy, or hearing loss. PMC

---

Causes

In arPEO, “causes” mainly means genes that must be inherited in two faulty copies. Each gene below has been linked to PEO and mitochondrial DNA maintenance problems. The gene list is broad because different clinics and studies report different mixes; the exact gene in one family may differ from another.

1. POLG – makes the main enzyme that copies mitochondrial DNA. Faulty POLG leads to errors and deletions in mitochondrial DNA, so muscles tire and weaken, especially eye muscles. NCBI+1

2. TWNK (also called PEO1) – makes the mitochondrial DNA helicase “Twinkle.” If Twinkle cannot unwind DNA properly, mitochondrial DNA breaks down and eye muscles fail slowly. Both dominant and recessive forms exist; recessive variants can cause arPEO. PMC+1

3. RRM2B – supplies building blocks for mitochondrial DNA. Low or faulty supply causes DNA depletion or deletions and PEO. Recessive and dominant forms are described. NCBI+1

4. SLC25A4 (ANT1) – helps move energy molecules (ADP/ATP) across the mitochondrial inner membrane. Defects stress mitochondria and lead to muscle weakness including PEO. MedlinePlus

5. POLG2 – accessory subunit that helps POLG work. Faults reduce the stability of the mitochondrial DNA copying complex, causing PEO. PubMed

6. DNA2 – a DNA repair/helicase enzyme in mitochondria; defects impair repair, leading to deletions and PEO features. (Reported in PEO cohorts as a nuclear cause of multiple deletions.) PubMed

7. RNASEH1 – involved in processing RNA–DNA hybrids during mitochondrial DNA replication; variants can cause adult PEO with multiple deletions. PubMed

8. TYMP (causes MNGIE) – abnormal nucleoside breakdown poisons mitochondrial DNA replication; PEO is common in this recessive disease. PubMed

9. TK2 – thymidine kinase 2 deficiency limits DNA building blocks inside mitochondria, so mtDNA falls and PEO or generalized myopathy may appear. PubMed

10. MGME1 – DNA nuclease needed for proper mtDNA processing; loss causes multiple deletions and PEO-like myopathy. PubMed

11. OPA1 – better known for optic atrophy, but some families show external ophthalmoplegia as part of the spectrum. PubMed

12. SPG7 – a protease (paraplegin) in mitochondria; some patients have PEO with multiple deletions. PubMed

13. MPV17 – inner-membrane protein; defects lead to mtDNA maintenance issues and sometimes PEO in adults. PubMed

14. DGUOK – mitochondrial deoxyguanosine kinase; mtDNA depletion can cause myopathy with PEO features. PubMed

15. RNF185 and related maintenance genes – rare reports link these to adult PEO phenotypes with multiple deletions. PubMed

16. Single large-scale mtDNA deletion – not inherited recessively, but worth noting because it can mimic arPEO clinically with the same eye findings. PubMed

17. Multiple mtDNA deletions (undetermined nuclear gene) – some adults have characteristic biopsy DNA changes and PEO without a known gene yet. Frontiers

18. RARS2 and other mitochondrial translation genes – rare adult reports include ophthalmoplegia phenotypes when mitochondrial protein synthesis falters. PubMed

19. AIFM1 (X-linked) – not recessive autosomal, but important differential with external ophthalmoplegia in mitochondrial disease. PubMed

20. Environmental triggers on top of genetic risk – illness, certain drugs, or metabolic stress can unmask or worsen symptoms when the genetic foundation is present, because energy demands rise beyond mitochondrial capacity. (General mitochondrial disease principle.) ScienceDirect

---

Common symptoms

1. Droopy eyelids (ptosis). The first sign for many people. It may start on one side and later involve both lids. People may tilt the head back to see. MedlinePlus

2. Slowly reduced eye movements. Looking up, down, or sideways becomes hard. It gets worse over years, not days. PMC

3. Little or no double vision. Because the problem is symmetric and gradual, the brain adapts, so double vision is often mild or absent compared with nerve palsies. Lippincott

4. Tired, heavy feeling around the eyes. Lids feel heavy by evening. People may recruit forehead muscles to keep eyes open. MedlinePlus

5. Exercise intolerance. Activities feel harder than expected for age, due to mitochondrial energy shortage. PubMed

6. Mild facial weakness. Smiling or closing eyes tightly can be slightly weak in some patients. PubMed

7. Neck flexor weakness. Holding the head up can tire faster. PubMed

8. Limb muscle weakness (later). Legs or arms may weaken after the eye problems are established. PMC

9. Balance trouble or ataxia (in some). Especially with certain gene types like POLG. NCBI

10. Tingling or numbness (peripheral neuropathy) in some people. Again more common in specific gene forms. NCBI

11. Hearing difficulties (sometimes). Part of broader mitochondrial involvement in “PEO-plus.” PMC

12. Swallowing difficulty or nasal speech (occasionally). From weakness in throat muscles. PubMed

13. Headache or migraine-like symptoms (occasional). Mitochondrial disorders can present with headache patterns. PubMed

14. Fatigue out of proportion to activity. A hallmark of mitochondrial myopathy. PubMed

15. Very slow progression. Changes build over years. This slow course helps tell arPEO apart from acute disorders. Lippincott

---

Diagnostic tests

A) Physical examination

1. Eyelid exam with measurements (MRD1, levator function). The clinician measures lid height and lifting power. In arPEO, lid elevation is weak and improves little with effort. This sets a baseline and guides eyelid surgery decisions later. Medscape

2. Ocular motility charting. The doctor maps movement in all directions. PEO shows symmetric, slow loss of range rather than sudden palsy in one direction. This pattern supports a mitochondrial myopathy rather than a nerve lesion. PMC

3. Fatigability checks (sustained upgaze). Brief tests look for rapid, fluctuating weakness. In arPEO, weakness is steady and not dramatically fluctuating, which helps separate it from myasthenia gravis. PubMed

4. Cover–uncover and prism testing. Detects misalignment. Many arPEO patients have small, stable deviations with limited diplopia. Pattern helps distinguish chronic muscle weakness from acute nerve palsy. Lippincott

5. General neurologic and muscle exam. Looks for “PEO-plus”: limb weakness, reflex changes, sensory loss, ataxia, or hearing issues that point toward certain genes (e.g., POLG). NCBI

B) Simple bedside/manual tests

6. Ice-pack test (on the ptotic lid). Cooling briefly can lift a myasthenic lid but usually does not help in arPEO. A negative ice-pack test nudges the diagnosis away from myasthenia. PubMed

7. Cogan’s lid twitch and rest tests. These quick maneuvers favor myasthenia if positive; they are usually absent in arPEO, helping with the differential. PubMed

8. Edrophonium (Tensilon) history and modern alternatives. Historically used for myasthenia; not a routine arPEO test, but a lack of dramatic response argues for a myopathic process. (Modern practice relies more on antibody tests and SF-EMG for myasthenia.) PubMed

9. Functional vision assessments (reading, head posture). Documenting chin-up posture or brow recruitment shows real-life impact and supports the need for supportive care or lid surgery planning. Medscape

C) Laboratory and pathological tests

10. Serum creatine kinase (CK). Often normal or mildly raised in mitochondrial myopathy; helps rule out other myopathies with very high CK. ScienceDirect

11. Serum lactate (± pyruvate). May be elevated at rest or after exercise because mitochondria underperform; not specific but supportive. ScienceDirect

12. Mitochondrial stress biomarkers (FGF-21 and GDF-15). These blood tests can be high in mitochondrial myopathies and are good non-invasive clues before biopsy or genetics. MDPI

13. Comprehensive genetic testing (nuclear and mtDNA). Next-generation sequencing panels or exome sequencing look for biallelic variants in POLG, TWNK, RRM2B, SLC25A4, and others, plus mtDNA deletions/depletion. This is now the gold standard for confirming the cause. NCBI+2MedlinePlus+2

14. Muscle biopsy histology. Shows ragged-red fibers and COX-negative fibers—classic signs that muscle mitochondria are dysfunctional. Biopsy is less common now but still helpful in unclear cases. ScienceDirect

15. Molecular tests on muscle. Detect multiple mitochondrial DNA deletions or depletion, which strongly supports a nuclear-gene mitochondrial maintenance disorder causing PEO. PubMed

D) Electrodiagnostic tests

16. Standard needle EMG. Can show a mild myopathic pattern in facial or limb muscles. It does not show the clear transmission failure that myasthenia gravis shows, which helps the differential. PubMed

17. Single-fiber EMG (SF-EMG). Very sensitive for myasthenia; normal or only mildly abnormal results (without typical myasthenic pattern) push the diagnosis toward arPEO. PubMed

18. Repetitive nerve stimulation. Looks for a decrement pattern of myasthenia; a negative study again supports arPEO over a neuromuscular junction problem. PubMed

E) Imaging and ocular tests

19. Orbital MRI or CT. In arPEO/CPEO, extraocular muscles are thin and atrophic, unlike Graves orbitopathy where they are enlarged. This pattern is a strong clue. PMC+1

20. Ocular imaging (OCT) and brain MRI when needed. OCT may show subtle retinal or optic-nerve changes in some patients; brain MRI can be normal or show nonspecific white-matter or cerebellar changes in syndromic cases. These help define the “plus” features. EyeWiki

Non-pharmacological treatments (therapies & others)

1. Custom eyelid crutches (spectacle-mounted)
   Description: A thin, light bar attached to eyeglass frames props the upper lids so more light enters the eyes and the field of vision opens. An optician adjusts the height and spring so the bar lifts the lid without scratching the cornea. Many patients use crutches during reading, driving, or computer work and remove them for rest. Proper fit plus regular artificial tears lowers friction and irritation.
   Purpose: Reduce vision blockage from drooping lids without surgery.
   Mechanism: Provides a mechanical counter-lift to ptotic lids, substituting for weak levator/Müller’s muscles so the pupil clears. EyeWiki

2. Ptosis taping for short tasks
   Description: Hypoallergenic eyelid tape gently holds the lid higher for short activities (reading, cooking, meetings). Users clean the skin, place the tape so it does not pull lashes, and remove it slowly to protect the skin. It is inexpensive and reversible, but not ideal for long wear or thin skin. Always pair with lubricants to prevent exposure dryness.
   Purpose: Quick, temporary lid elevation for part-day tasks.
   Mechanism: External adhesion counteracts gravity on a weakened eyelid to uncover the visual axis. EyeWiki

3. Lubrication routine (non-Rx tears/gel/night ointment)
   Description: Regular use of demulcent artificial tears during the day, gel at dusk, and petrolatum/mineral-oil ointment at night protects the cornea if lids don’t close fully. Choose drops from the FDA OTC ophthalmic monograph (e.g., carboxymethylcellulose, hypromellose, PEG/PG) and preservative-free vials if dosing >4×/day or if eyes are sensitive. Add a humidifier and frequent screen breaks (20-20-20 rule).
   Purpose: Prevent exposure keratopathy, burning, and fluctuating blur.
   Mechanism: Demulcents form a protective moisture film; gels/ointments slow evaporation overnight. eCFR+2eCFR+2

4. Wraparound sunglasses & moisture chamber goggles
   Description: Curved sunglasses or moisture chamber glasses (with gasket) block wind and slow tear evaporation outdoors and in air-conditioned rooms. Clear, anti-fog options help at night or for screen work.
   Purpose: Reduce dryness, light sensitivity, and reflex blinking.
   Mechanism: Physical barrier retains humidity at the ocular surface, lowering evaporative loss. WebEye

5. Lid hygiene & warm compresses
   Description: Gentle cleanser (dilute baby shampoo or commercial lid wipes) and warm compresses 5–10 minutes twice daily support meibomian oil flow so tears last longer.
   Purpose: Improve tear film stability to ease exposure symptoms.
   Mechanism: Heat softens meibum; massage expresses oil to stabilize the lipid layer. WebEye

6. Prism or posture strategies for diplopia
   Description: If limited eye movement causes double vision in certain gazes, an optometrist can trial small Fresnel prisms on glasses for those positions. Some patients learn chin-up or head-turn strategies that align vision for reading or walking.
   Purpose: Reduce double vision and improve navigation safety.
   Mechanism: Prism bends incoming light to a more comfortable retinal alignment when muscles cannot move eyes fully. EyeWiki

7. Nighttime lid taping or moisture shields
   Description: For incomplete closure (lagophthalmos), lightly tape lids shut or use a soft moisture shield at bedtime after ointment.
   Purpose: Protect the cornea during sleep.
   Mechanism: Maintains a closed, humid environment to prevent overnight exposure injury. eCFR

8. Aerobic exercise training (graded, supervised)
   Description: Low-to-moderate cycling or brisk walking 3–5 days/week improves stamina and quality of life in mitochondrial myopathy, with careful pacing to avoid overexertion. Start low, progress slowly, and monitor symptoms.
   Purpose: Boost whole-body function and fatigue management.
   Mechanism: Endurance training raises oxidative capacity and mitochondrial adaptations without worsening mutation load in studied cohorts. OUP Academic+2Frontiers+2

9. Light resistance training
   Description: 2–3 sessions/week of low-load resistance for limbs and neck improves functional strength (sit-to-stand, stair climbing). Keep reps modest, rest longer, and stop if pain or severe fatigue occurs.
   Purpose: Enhance safety in daily activities without flares.
   Mechanism: Muscle training improves neuromuscular efficiency and can complement aerobic gains in mitochondrial disease. SpringerLink

10. Energy conservation & activity pacing
    Description: Plan errands, batch tasks, sit for grooming/cooking, and use assistive tools (reacher, lightweight cookware). Brief rests prevent “push-and-crash” cycles.
    Purpose: Reduce fatigue and maintain independence.
    Mechanism: Pacing matches energy output to available oxidative capacity in mitochondrial myopathy. PMC

11. Falls-prevention home setup
    Description: Improve lighting, remove loose rugs, and add railings. If diplopia or neck extensor weakness affects balance, ask for a physical therapy home safety check.
    Purpose: Prevent injuries from missteps or reduced peripheral vision.
    Mechanism: Environmental modifications lower fall risk when ocular motility and head posture are limited. PMC

12. Vision rehabilitation strategies
    Description: Low-vision services teach contrast enhancement, task lighting, and magnification. Apps and screen readers aid reading on fatigued days.
    Purpose: Preserve productivity despite visual restriction.
    Mechanism: Compensatory tools bypass mechanical eye-movement limits to optimize remaining visual function. Genetic Rare Diseases Center

13. Driving adaptations
    Description: Use daytime routes, anti-glare visors, and frequent rest stops. If lids obstruct vision, wear crutches or tape; if diplopia persists, seek specialist advice and follow local rules.
    Purpose: Maintain safe mobility.
    Mechanism: Compensatory positioning and optics improve visual fields while respecting legal standards. EyeWiki

14. Workstation ergonomics
    Description: Raise screens, enlarge fonts, and use voice input. Frequent blink reminders and humidifier at the desk reduce irritation.
    Purpose: Reduce strain during computer work.
    Mechanism: Ergonomics minimizes upward gaze and dryness that aggravate ptosis symptoms. WebEye

15. Sun/UV protection & hat brim
    Description: Broad-brim hat plus UV-blocking eyewear eases photophobia and squinting.
    Purpose: Comfort outdoors and less reflex eye rubbing.
    Mechanism: Reduces light scatter and evaporation on the ocular surface. WebEye

16. Speech/swallow review if CPEO-plus
    Description: If throat muscles tire (rare but reported in CPEO-plus), a speech-language pathologist can assess swallowing and teach safe-swallow strategies.
    Purpose: Prevent choking and weight loss.
    Mechanism: Compensatory maneuvers reduce aspiration when oropharyngeal muscles are weak. NCBI

17. Hearing support if needed
    Description: Audiology checks and hearing aids improve communication where sensorineural loss coexists.
    Purpose: Preserve social function and safety.
    Mechanism: Amplification compensates for cochlear dysfunction sometimes seen in mitochondrial syndromes. NCBI

18. Fatigue management education
    Description: Teach prioritization, napping before tasks, and “banking” energy for important events.
    Purpose: Reduce crash days and maintain routines.
    Mechanism: Behavioral pacing aligns activity with limited ATP production. PMC

19. Psychological support
    Description: Counseling for adaptation, anxiety, or low mood from chronic symptoms; peer groups (mitochondrial disease foundations) help with coping.
    Purpose: Improve quality of life and adherence to plans.
    Mechanism: Cognitive and social strategies reduce perceived burden and improve self-management. UMDF

20. Surgical correction when appropriate (see surgeries below)
    Description: When non-surgical options no longer keep the visual axis clear, eyelid surgery is considered. Choosing the right technique is critical in AR-PEO.
    Purpose: Lasting lid elevation and clearer vision.
    Mechanism: Mechanical repositioning of the lid margin when levator function is poor. EyeWiki

Drug treatments

1. Oxymetazoline 0.1% ophthalmic (UPNEEQ®)
   Class: α-adrenergic agonist. Dose/Time: 1 drop once daily to affected eye(s). Purpose: Temporarily lifts upper eyelid if Müller’s muscle responds, helping vision in ptosis. Mechanism: Stimulates α-adrenergic receptors in Müller’s muscle, causing elevation. Side effects: Punctate keratitis, rebound redness, headache; caution with cardiovascular disease and MAO inhibitors. FDA status: Approved for acquired blepharoptosis; AR-PEO use is off-label and response varies with myogenic ptosis. FDA Access Data+2FDA Access Data+2

2. Cyclosporine 0.05% ophthalmic emulsion (RESTASIS®/RESTASIS Multidose®)
   Class: Calcineurin inhibitor immunomodulator. Dose/Time: 1 drop BID ~12 hours apart. Purpose: Increase tear production when dry eye inflammation reduces tearing (exposure risk from poor blink/closure). Mechanism: Inhibits T-cell–mediated ocular surface inflammation, improving basal tearing. Side effects: Burning, redness; benefits build over months. FDA status: Approved for keratoconjunctivitis sicca; used in AR-PEO to protect the cornea. FDA Access Data+2FDA Access Data+2

3. Lifitegrast 5% ophthalmic solution (XIIDRA®)
   Class: LFA-1 antagonist anti-inflammatory. Dose/Time: 1 drop BID ~12 hours apart. Purpose: Relieve signs/symptoms of dry eye disease in exposure-prone AR-PEO. Mechanism: Blocks LFA-1/ICAM-1 interaction to reduce T-cell activation on the ocular surface. Side effects: Dysgeusia, irritation, transient blurred vision. FDA status: Approved for dry eye disease; AR-PEO use is supportive. FDA Access Data+2FDA Access Data+2

4. Artificial tears (OTC demulcents under FDA Monograph 21 CFR Part 349)
   Class: Demulcents (e.g., carboxymethylcellulose, hypromellose, PEG/PG). Dose/Time: 1–2 drops up to QID or more (preservative-free if frequent). Purpose: First-line for dryness from incomplete blink/closure. Mechanism: Polymer film reduces friction and stabilizes tear layer. Side effects: Minimal; preservative sensitivity possible. FDA status: Marketed under OTC Monograph; not disease-specific. eCFR+2eCFR+2

5. Lubricating ophthalmic ointment (white petrolatum/mineral oil; OTC)
   Class: Ocular emollient. Dose/Time: Small ribbon HS (bedtime) or PRN severe dryness. Purpose: Overnight corneal protection when eyelids don’t close completely. Mechanism: Occlusive layer limits evaporation for hours. Side effects: Temporary blur after application. FDA status: OTC Monograph product. FDA Access Data

6. Carboxymethylcellulose 0.5–1% (specific demulcent example)
   Class: Cellulose-derivative demulcent. Dose/Time: 1 drop up to QID–Q6H; preservative-free if frequent. Purpose: Daytime lubrication. Mechanism: Viscous polymer increases dwell time. Side effects: Transient blur; rarely allergy. FDA status: OTC Monograph active. eCFR

7. Polyethylene glycol/propylene glycol combo (example: PEG/PG tears)
   Class: Demulcents. Dose/Time: 1 drop up to QID. Purpose: Stabilize tear film in A/C or windy settings. Mechanism: Polymer blend retains water and reduces shear. Side effects: Mild transient sting possible. FDA status: OTC Monograph active. eCFR

8. Hydroxypropyl guar gel drops (viscoelastic tear supplement)
   Class: Demulcent/gel former. Dose/Time: 1 drop QID or PRN. Purpose: Bridge between drops and ointment. Mechanism: Gel network enhances retention; cushions cornea. Side effects: Temporary blur. FDA status: OTC Monograph category. FDA Access Data

9. Topical antibiotic ointment (e.g., erythromycin) for exposure keratopathy at clinician’s discretion
   Class: Macrolide antibiotic. Dose/Time: Thin ribbon HS for limited periods if epithelial defects/infection risk. Purpose: Protects compromised cornea when exposure leads to erosions. Mechanism: Inhibits bacterial protein synthesis on ocular surface. Side effects: Hypersensitivity; avoid unnecessary prolonged use. FDA status: Prescription antibiotic; indication is superficial ocular infection—use targeted by clinician. eCFR

10. Short course of mild topical steroid for acute surface inflammation (clinician-directed)
    Class: Ophthalmic corticosteroid. Dose/Time: Low-dose, short duration with IOP checks. Purpose: Tame severe inflammatory flares unresponsive to lubricants. Mechanism: Genomic anti-inflammatory effects reduce cytokines and cell infiltration. Side effects: IOP rise, cataract with prolonged use—specialist monitoring required. FDA status: Approved for ocular inflammation; AR-PEO use is supportive. PMC

11. Punctal plug instillation (adjunct—not a drug but often paired with drops)
    Note: A device, not a medication; included here because it often reduces drop burden by conserving tears under clinician guidance. Purpose/Mechanism: Decreases drainage to keep tears longer on the eye. Risks: Epiphora, extrusion. EyeWiki

12. Botulinum toxin (onabotulinumtoxinA) for coexisting blepharospasm
    Class: Neuromuscular blocker. Dose/Time: Per label for blepharospasm; injections every 3–4 months. Purpose: If eyelid spasm coexists (not typical of AR-PEO), reduces spasm so vision is steadier. Mechanism: Blocks acetylcholine release at neuromuscular junction. Side effects: Ptosis, dry eye, diplopia. FDA status: Approved for blepharospasm; unrelated to AR-PEO itself. PMC

13. (Reserved for clinician) Hypertonic saline 5% drops/ointment for recurrent corneal edema/erosion
    Class: Hyperosmotic. Dose/Time: QID drops or HS ointment. Purpose: Dehydrate corneal epithelium in specific edema states. Mechanism: Osmotic gradient draws fluid out. Side effects: Sting; use only when indicated. FDA status: OTC Monograph category. FDA Access Data

14. Prescription nighttime goggles with continuous moisture (adjunctive therapy)
    Note: Accessory to reduce need for frequent drops; improves comfort. Mechanism: Maintains micro-climate over cornea. WebEye

15. Topical anti-inflammatory sequence (clinician plan): cyclosporine or lifitegrast + lubricants
    Rationale: For moderate-severe dry eye from exposure, starting an anti-inflammatory drop while maintaining tears lowers long-term surface damage. Mechanism/Side effects: As above. FDA status: As labeled above. FDA Access Data+1

Beyond ocular-surface and ptosis support, there are no FDA-approved systemic drugs that treat or reverse AR-PEO. “Mitochondrial cocktails” (e.g., CoQ10, riboflavin, L-carnitine) are commonly tried, but high-quality evidence is limited; these are usually managed as dietary supplements (see below), not FDA-approved drugs for AR-PEO. Your care team may also treat coexisting issues (e.g., neuropathic pain, mood) with standard medicines, but those are not AR-PEO-specific. Cochrane+1

Dietary molecular supplements

1. Coenzyme Q10 (ubiquinone/ubiquinol)
   Dose: 100–300 mg/day (divided); some use higher. Function: Electron carrier in the respiratory chain; supports ATP synthesis. Mechanism: May improve mitochondrial oxidative phosphorylation and act as an antioxidant; mixed clinical data in primary mitochondrial disease, but often tried due to biologic plausibility and safety. Notes: Take with fat for absorption; watch for GI upset. Discuss drug interactions (e.g., warfarin). Evidence across mitochondrial disorders is variable; not an FDA-approved AR-PEO therapy. Cochrane

2. Riboflavin (vitamin B2)
   Dose: 100–400 mg/day. Function: Precursor of FAD/FMN coenzymes in complexes I and II. Mechanism: Supports flavoprotein-dependent mitochondrial enzymes; anecdotal benefits in some mitochondrial myopathies. Notes: Harmless yellow urine; rare GI upset. PMC

3. Thiamine (vitamin B1)
   Dose: 100–300 mg/day. Function: Cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase. Mechanism: Supports carbohydrate entry into the TCA cycle. Notes: Generally safe; limited direct AR-PEO data. PMC

4. L-carnitine
   Dose: 1–3 g/day (divided). Function: Transports long-chain fatty acids into mitochondria. Mechanism: May improve fatty-acid oxidation in some patients; can reduce fatigue or cramping for a subset. Notes: Fishy odor, GI upset possible. PMC

5. Alpha-lipoic acid
   Dose: 300–600 mg/day. Function: Antioxidant and mitochondrial cofactor. Mechanism: Recycles other antioxidants; supports dehydrogenase complexes. Notes: Can affect glucose; monitor in diabetes. PMC

6. Creatine monohydrate
   Dose: 3–5 g/day. Function: Rapid phosphate donor for ATP resynthesis. Mechanism: Buffers energy in muscle; some small studies in mitochondrial myopathy suggest symptom benefit. Notes: Hydrate well; monitor in kidney disease. Cochrane

7. Vitamin D
   Dose: Per level (often 1,000–2,000 IU/day). Function: Bone/muscle support, immunity. Mechanism: Supports musculoskeletal health when overall activity is limited by fatigue. Notes: Check serum 25-OH vitamin D. PMC

8. Magnesium
   Dose: 200–400 mg/day (glycinate or citrate forms). Function: Cofactor in ATP metabolism and muscle relaxation. Mechanism: May aid cramp management and energy enzymes; evidence is general, not AR-PEO-specific. Notes: Loose stools (citrate). PMC

9. N-acetylcysteine (NAC)
   Dose: 600–1,200 mg/day. Function: Glutathione precursor. Mechanism: Antioxidant support may lower oxidative stress burden in mitochondrial disorders; human AR-PEO data are limited. Notes: GI upset possible; watch drug interactions. PMC

10. Omega-3 fatty acids (EPA/DHA)
    Dose: 1–2 g/day combined EPA/DHA. Function: Anti-inflammatory; may help ocular surface. Mechanism: Modulates lipid layer and systemic inflammation. Notes: Fishy aftertaste; caution with anticoagulants. PMC

Immunity-booster / regenerative / stem-cell” drugs

There are no FDA-approved regenerative or stem-cell drugs for AR-PEO. Below are research-focused or related concepts to understand the landscape:

1. Elamipretide (SS-31) — a mitochondria-targeted peptide studied in primary mitochondrial myopathy (PMM). Phase-3 MMPOWER-3 did not meet endpoints overall, though post-hoc signals in nuclear DNA “replisome” subtypes led to the ongoing NuPOWER trial. In September 2025, elamipretide received FDA approval for Barth syndrome, a different mitochondrial disease—not AR-PEO. Any AR-PEO use remains investigational. UMDF+3PubMed+3BioMed Central+3

2. Mitochondrial gene therapy approaches (preclinical/early clinical) — strategies like allotopic expression or editing aim to correct mitochondrial defects; none are approved for AR-PEO. PMC

3. Nicotinamide riboside / NAD+ pathway agents — explored for mitochondrial support in research; not FDA-approved for AR-PEO and remain supplements in the U.S. Portland Press

4. mTOR pathway modulators / exercise-mimetics — experimental concepts to enhance mitochondrial biogenesis; clinical translation for AR-PEO is unproven. SpringerLink

5. Mitochondria-targeted antioxidants (e.g., MitoQ) — available as supplements; not drugs approved for AR-PEO. Cochrane

6. Stem-cell–based therapies — not approved for AR-PEO; avoid commercial “stem-cell clinics” that make unsubstantiated claims. Follow clinical trial registries and major centers only. PMC

Surgeries

Frontalis suspension (sling) with silicone rod.
Procedure: A thin sling connects the upper eyelid to the forehead frontalis muscle so the brow can help lift the lid. Silicone allows later adjustment. Why: Best when levator function is very weak (common in AR-PEO) and non-surgical measures fail. Evidence supports safety and efficacy for CPEO-related ptosis. EyeWiki+2PubMed+2

Levator advancement/resection (selected cases).
Procedure: Tightens or advances the levator aponeurosis to raise the lid. Why: Considered if some levator function remains; risks include lagophthalmos if over-tightened—caution in AR-PEO. EyeWiki

Brow ptosis repair (adjunct).
Procedure: Lifts the brow to reduce lid redundancy and assist sling outcomes. Why: Helps when brow descent adds to visual obstruction. EyeWiki

Temporary frontalis suture suspension (“trial lift”).
Procedure: Short-term suture to simulate sling effect before permanent surgery. Why: Helps patients judge field improvement and dryness risk. EyeWiki

Tarsorrhaphy (partial).
Procedure: Partially sutures eyelids at the outer corner to narrow the opening. Why: For severe exposure keratopathy when elevation causes dryness; protects the cornea. EyeWiki

Preventions

1. Daytime lubrication and night ointment to prevent exposure injury. FDA Access Data

2. Wraparound or moisture-chamber eyewear in wind/AC. WebEye

3. Blink breaks (every 20 minutes, 20 seconds) during screens. WebEye

4. Humidifier at home/desk to reduce evaporation. WebEye

5. Avoid smoke and drafts that dry the ocular surface. WebEye

6. Maintain graded aerobic activity to support stamina. OUP Academic

7. Plan tasks with rests; avoid “push-crash.” PMC

8. Keep regular eye checks to monitor cornea and IOP if on steroids or immunomodulators. FDA Access Data

9. Protect eyes during sleep (tape/moisture shield). FDA Access Data

10. Seek early help for new double vision, pain, or sudden redness. EyeWiki

When to see doctors

See an ophthalmologist promptly if you have sudden eye pain, sharp vision drop, corneal abrasion symptoms (gritty pain, light sensitivity), new constant double vision, ulcers, or inability to close the eye. Arrange routine follow-ups for surface checks, refraction, and to reassess whether non-surgical measures still suffice. Ask a neurologist/geneticist to confirm the genetic cause and screen for “CPEO-plus” features (hearing, neuropathy, endocrine, cardiac). A physical therapist can tailor exercise safely. Because no AR-PEO-specific drug exists yet, care is multidisciplinary and preventive. NCBI+1

What to eat and what to avoid

What to eat (5):

1. Balanced, Mediterranean-style pattern (vegetables, fruits, whole grains, lean proteins) to support general mitochondrial health. PMC

2. Adequate protein with each meal to maintain muscle. PMC

3. Omega-3 sources (fatty fish, flax) for ocular surface and anti-inflammatory support. PMC

4. Hydration to sustain tear film quality. WebEye

5. If using supplements (e.g., CoQ10, riboflavin), take with clinician guidance and food when appropriate. Cochrane

What to avoid (5):

1. Smoking/vape exposure—worsens dryness and oxidative stress. PMC

2. Very dry, windy environments without eye protection. WebEye

3. Excessive caffeine/alcohol that dehydrate. WebEye

4. Unregulated “stem-cell” or “mitochondria cures” advertised online. PMC

5. Overexertion workouts that leave you wiped out for days—build up slowly instead. OUP Academic

FAQs

1) Is AR-PEO curable?
No cure yet. Care focuses on eyelid support, dry-eye protection, and safe, graded exercise to preserve function. NCBI

2) Will the droopy lids always get worse?
Progression is typically slow over years. Regular reviews help time non-surgical vs. surgical options. NCBI

3) Are there FDA-approved medicines for AR-PEO?
No drug is FDA-approved specifically for AR-PEO. Some FDA-approved eye medicines (e.g., UPNEEQ®, RESTASIS®, XIIDRA®) treat ptosis or dry eye, not AR-PEO itself. FDA Access Data+2FDA Access Data+2

4) Can UPNEEQ® help my AR-PEO ptosis?
Sometimes—it lifts lids by stimulating Müller’s muscle. Response is variable in myogenic ptosis and use is off-label for AR-PEO. FDA Access Data

5) Do artificial tears really matter?
Yes. Monograph-listed demulcents protect the cornea and reduce irritation from exposure; use them consistently. eCFR+1

6) Is surgery safe in AR-PEO?
When chosen carefully, frontalis sling has good outcomes and is widely used in CPEO-related ptosis; surgeon selection and technique are key. EyeWiki+1

7) Will exercise make my mitochondria worse?
Studies support graded aerobic training as safe and beneficial in mitochondrial myopathy when supervised—avoid sudden overexertion. OUP Academic

8) Which supplement helps most?
CoQ10 is commonly tried; others include riboflavin and L-carnitine. Evidence is mixed; personalize with your clinician. Cochrane

9) Are “mitochondrial cocktails” FDA-approved?
No. They are dietary supplements; discuss quality, dose, and interactions. Cochrane

10) Can prism glasses fix all double vision?
They help in limited gaze positions; severe ophthalmoplegia may outstrip prism range, so strategies and rehab still matter. EyeWiki

11) Why do I need dry-eye anti-inflammatory drops?
Chronic exposure can inflame the surface. Cyclosporine or lifitegrast can increase tears and comfort over months. FDA Access Data+1

12) Are there gene therapies for AR-PEO?
Not approved. Research is ongoing; monitor trials through major centers. PMC

13) What if I wake with a painful, red eye?
Call urgently—could be exposure keratopathy or ulcer; you may need bandage contact lens or other care. EyeWiki

14) Does AR-PEO affect life span?
Many live normal lifespans, especially with eye-surface protection and fitness; CPEO-plus complications need monitoring. NCBI

15) What’s new in research?
Mitochondria-targeted agents like elamipretide have mixed trial results in PMM; in 2025 it gained FDA approval for Barth syndrome (not AR-PEO). Subtype-focused trials continue. PubMed+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.